Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Smith, U.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Thiazolidinedione-induced effects beyond glycaemic control

Ulf Smith

Department of Internal Medicine, The Sahlgrenska Academy, S-413 45 Göteborg, Sweden, ulf.smith{at}medic.gu.se

The thiazolidinediones exert their insulin sensitising effect by binding to the nuclear receptors (transcription factors) peroxisome proliferator activated receptor (PPAR) {gamma} and, to varying degrees, to PPAR{alpha}. Several different genes are activated by thiazolidinediones, many of which contribute to the increase in insulin sensitivity (eg. an increase in glucose uptake and utilisation, a decrease in gluconeogenesis and in insulin-antagonistic cytokines, such as tumour necrosis factor {alpha}). Activation of other genes indirectly reduces insulin resistance by, for example, increasing free fatty acid (FFA) uptake and oxidation resulting in lower circulating FFA levels. The action of thiazolidinediones at PPAR{gamma} is generally responsible for their insulin sensitising effects while action at PPAR{alpha} contributes to their lipid lowering effects. Therefore, the relative affinities of the different thiazolidinediones for PPAR{gamma} and PPAR{alpha} will also lead to a different spectrum of actions for each agent.

Key Words: diabetic dyslipidaemia • insulin resistance • PPAR receptors • pioglitazone • thiazolidinedione.

References

  • Willson TM, Brown PJ, Sternbach DD, Henke BR The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rosen ED, Spiegelman BM PPAR{gamma}: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-4.[Free Full Text]
  • Auwerx J. PPAR{gamma}, the ultimate thrifty gene. Diabetologia 1999;42:1033-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.[Abstract]
  • Mori H., Ikegami H., Kawaguchi Y. et al. The Pro12--->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-4.[Abstract/Free Full Text]
  • Barroso I., Gurnell M., Crowley VEF et al. Dominant negative mutations in human PPAR{gamma} associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sakamoto J., Kimura H., Moriyama S. et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Campbell IW Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000;60:1017-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • El-Kebbi IM, Roser S., Pollet RJ Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 1994;43:953-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sandouk T., Reda D., Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 1993;133:352-9.[Abstract/Free Full Text]
  • Hofmann C., Lorenz K., Colca JR Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991;129:1915-25.[Abstract/Free Full Text]
  • Hayakawa T., Shiraki T., Morimoto T. et al. Pioglitazone improves insulin signalling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Commun 1996;223:439-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Smith U., Gogg S., Johansson A., Olausson T., Rotter V., Svalstedt B. Thiazolidinediones (PPAR{gamma} agonists) but not PPAR{alpha} agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 2001;15: 215-20.[Abstract/Free Full Text]
  • Hofmann CA, Edwards CWI, Hillman RM et al. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: elevation of liver GLUT 2 and phosphoenolpyruvate carboxykinase expression. Endocrinology 1992;130:735-40.[Abstract/Free Full Text]
  • Hofmann C., Lorenz K., Williams D., Palazuk BJ, Colca JR Insulin sensitisation in diabetic rat liver by an antihyperglycemic agent. Metabolism 1995;44:384-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sugiyama Y., Shimura Y., Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneimittelforschung 1990;40:436-40.[Medline] [Order article via Infotrieve]
  • Nishimura Y., Inoue Y., Takeuchi H., Oka Y. Acute effects of pioglitazone on glucose metabolism in perfused rat liver. Acta Diabetol 1997;34:206-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hallakou S., Doare L., Foufelle F. et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46:1393-9.[Abstract]
  • Swanson ML, Bleasdale JE Antidiabetic agent pioglitazone increases insulin receptors on 3T3-L1 adipocytes. Drug Dev Res 1995;35:69-82.[CrossRef][Web of Science]
  • Murase K., Odaka H., Suzuki N., Tayuki N., Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-{alpha} level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 1998; 41:257-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Miyazaki Y., Mahankali A., Matsuda M. et al. Improved glycaemic control and enhanced insulin sensitivity in Type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-9.[Abstract/Free Full Text]
  • Yamasaki Y., Kawamori R., Wasada T. et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. Tohuku J Exp Med 1997;183:173-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Roden M., Price TB, Perseghin G. et al. Mechanism of free fatty-acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859-65.[Web of Science][Medline] [Order article via Infotrieve]
  • Rebrin K., Steil GM, Getty L., Bergman RN Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995;44:1038-45.[Abstract]
  • Groop L., Orho-Melander M. The dysmetabolic syndrome. J Intern Med 2001;250:105-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Laakso M. Insulin resistance and cardiovascular disease. Br J Diabetes Vasc Dis 2002;2(suppl 1):S7-S9.
  • Brunetti P. Pioglitazone - current profile. Br J Diabetes Vasc Dis 2002;2 (suppl 1):S16-S21.
  • Carey GB Mechanisms regulating adipocyte lipolysis. Adv Exp Med Biol 1998;441:157-70.[Web of Science][Medline] [Order article via Infotrieve]
  • Engfeldt P., Arner P., Bolinder J., Ostman J. Phosphodiesterase activity in human subcutaneous adipose tissue in insulin- and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1982;55:983-8.[Abstract/Free Full Text]
  • Tang Y., Osawa H., Onuma H., Nishimiya T., Ochi M., Makino H. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 1999;48:1830-5.[Abstract]
  • Kletzien RF, Clarke SD, Ulrich RG Enhancement of adipocyte differentiation by an insulin sensitising agent. Mol Pharmacol 1992;41:393-8.[Abstract]
  • King AB A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23:557.[Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1 suppl, S24-S27 (2002)
DOI: 10.1177/14746514020020010601
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Smith, U.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?